Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GEN1106

Antibody-drug conjugate · Cytotoxic, directed at SLITRK6 · developed by Genmab

Phase 1 Most advanced trial
GMAB Developer
1 Registered trials

What is GEN1106?

GEN1106 is an antibody-drug conjugate whose monoclonal antibody binds SLITRK6, a leucine-rich repeat neuronal transmembrane protein overexpressed on some cancer cells. After binding and internalization, a cytotoxic agent is released to kill the SLITRK6-expressing cells. It is studied in solid tumors and urothelial carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
SLITRK6
Mechanism
Cytotoxic, directed at SLITRK6
Therapy area
Oncology
Developer
Genmab (GMAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07416123 Phase 1 Solid Tumors Recruiting GMAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid TumorsUrothelial Carcinoma

More from Genmab

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the GMAB page.

Follow GMAB, the company behind GEN1106

See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GMAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.